Duality Biotherapeutics (FRA:4ZB) Buyback Yield %: -0.03 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Buyback Yield %?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Buyback Yield % is -0.03 as of Sep. 16, 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 703 Biotechnology companies, Duality Biotherapeutics ranks better than 85.63% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Duality Biotherapeutics's current buyback yield was -0.03%.

Duality Biotherapeutics Buyback Yield % Related Terms

Duality Biotherapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Buyback Yield % Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -7.07

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Buyback Yield % 0.00 -6.91 0.00

FRA:4ZB vs VRTX, REGN, MRNA: Buyback Yield % Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's Buyback Yield % falls into.


FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Duality Biotherapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-10.284585077418 + 216.55266516528) / 2916.8262763689
=-7.07%

Duality Biotherapeutics's annualized Buyback Yield for the quarter that ended in Jun. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.567) /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -0.03 mean?
Duality Biotherapeutics (FRA:4ZB) has a Buyback Yield % of -0.03 as of Sep. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #101 out of 703 companies in the Biotechnology industry, placing it in the top 14.4%.
Is Duality Biotherapeutics' Buyback Yield % too high?
Duality Biotherapeutics' current Buyback Yield % is -0.03. Based on the distribution chart, Duality Biotherapeutics ranks #101 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #101 out of 703 companies for Buyback Yield %. This places Duality Biotherapeutics in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Buyback Yield % is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Buyback Yield % of -0.03. The current Buyback Yield % is -0.03. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Buyback Yield % is -0.03 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price